ArticleTranslational cancer research2026
Identifying research gaps in PIK3CA-mutant breast cancer: a bibliometric analysis of evolving trends and clinical applications.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations are among the most common genetic alterations in breast cancer and have important implications for tumor biology, subtype-specific behavior, and targeted therapy. This study provides a comprehensive bibliometric analysis of global research on PIK3CA mutations in breast cancer, highlighting critical research hotspots and evolving trends. We aim to address the current lack of an integrated understanding in this vital area. Methods: Publications related to PIK3CA and breast cancer from 2000 to 2024 were retrieved from the Web of Science Core Collection. Bibliometric cluster analyses were performed using VOSviewer, CiteSpace, and R-bibliometrix to delineate collaboration networks, journal distributions, and thematic clusters. Results: A total of 2,135 publications were analyzed, predominantly from the US, China, and the UK. Harvard University and Unicancer emerged as leading institutions, with significant contributions from authors such as Gordon B. Mills and Jorge S. Reis-Filho. Keyword analysis identified six major research hotspots, categorized into basic research (molecular mechanisms, signaling pathways, genomics, biomarkers, tumor biology) and clinical research (clinical trials, therapeutic strategies, cancer subtypes, drug resistance, tumor microenvironment). Citation burst analysis indicated an early focus on molecular mechanisms and gene mutations, while recent studies have shifted toward precision medicine, including liquid biopsy, advanced breast cancer subtypes, and targeted therapies such as alpelisib and fulvestrant, reflecting evolving priorities toward personalized treatment. Conclusions: This bibliometric study identifies six key research hotspots in PIK3CA and breast cancer, demonstrating the transition from basic mechanisms to clinical applications. Recent research trends, including liquid biopsy, advanced subtypes, and combination therapies, are closely tied to precision medicine and individualized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.